# A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer

> **NCT01228760** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 46 (actual)

## Conditions studied

- Prostate Neoplasms

## Interventions

- **DRUG:** ASG-5ME

## Key facts

- **NCT ID:** NCT01228760
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2013-06-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01228760

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01228760, "A Study to Determine the Maximum Tolerated Dose of ASG-5ME in Subjects With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01228760. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*